茂化實華(000637.SZ):第三季度淨利預增46.42%-119.63%
格隆匯10月12日丨茂化實華(000637.SZ)披露2021年前三季度業績預吿,預計2021年1-9月實現歸屬於上市公司股東的淨利潤3100萬元-3900萬元,同比增長73.40%-118.15%;預計2021年7-9月實現歸屬於上市公司股東的淨利潤800萬元-1200萬元,同比增長46.42%-119.63%。業績變動原因説明:
報吿期,隨着國內宏觀經濟復甦,化工生產經營形勢較好,公司抓住時機,積極挖潛增效,優化工藝技術和經濟指標,總體經營情況和業績同比有較大提升。
證券投資收益比上年同期減少285萬元(屬於非經常性損益)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.